Remiges Ventures
Overview
Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.
Investment Focus
- Early-stage drug discovery ventures developing advanced drugs
- Innovative assets from Japanese academic institutions
- Global investment opportunities in the life sciences sector
Portfolio Companies
Get the full list of 54,000+ investors
Remiges Ventures and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Remiges Ventures
What sectors does Remiges Ventures invest in?
Remiges Ventures invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices and Biotechnology, and is based in Cambridge, Massachusetts, United States. Remiges Ventures is listed as a venture capital in the ConnectSafely investor database.
What stage does Remiges Ventures invest at?
Remiges Ventures backs companies at Seed, Early Stage, Series A and Series B.
Which regions does Remiges Ventures invest in?
Remiges Ventures invests across United States, Japan, Europe and Israel.
Who are the partners at Remiges Ventures?
Team members listed for Remiges Ventures include Hiroshi Tamada (Chief Medical Officer) and Taro Inaba (Managing Partner).
What companies has Remiges Ventures invested in?
Remiges Ventures's portfolio includes Restore Vision, InFlectis BioScience, KisoJi Biotechnology and Qinotto.
How do I contact Remiges Ventures?
Remiges Ventures's contact details are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
